Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 17/20 | 0.65 |
| ▸ | AXL | P30530 | 2/20 | 0.42 |
| ▸ | MERTK | Q12866 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20929283 | 0.89 | CHRM1 (0.69) | CHRM1 | |
| SCHEMBL20929719 | 0.88 | CHRM1 (0.54) | CHRM1 | |
| SCHEMBL20929661 | 0.87 | CHRM1 (0.58) | CHRM1AXLMERTK | |
| SCHEMBL20929645 | 0.86 | CHRM1 (0.56) | CHRM1 | |
| SCHEMBL20929720 | 0.86 | CHRM1 (0.56) | CHRM1 | |
| SCHEMBL20929653 | 0.86 | CHRM1 (0.46) | CHRM1 | |
| SCHEMBL20929640 | 0.84 | CHRM1 (0.52) | CHRM1 | |
| SCHEMBL20929644 | 0.84 | CHRM1 (0.47) | CHRM1 | |
| SCHEMBL22264578 | 0.82 | CHRM1 (0.55) | CHRM1 | |
| SCHEMBL20929721 | 0.82 | CHRM1 (0.65) | CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3697790-B1 | HETEROARYL COMPOUNDS AS MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | SUVEN LIFE SCIENCES LTD (IN) | 2023-01-18 | — | — | EP | claimed |
| US-11234979-B2 | Heteroaryl compounds as muscarinic M1 receptor positive allosteric modulators | SUVEN LIFE SCIENCES LIMITED (IN) | 2022-02-01 | — | — | US | claimed |
| EP-3697790-B1 | HETEROARYL COMPOUNDS AS MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | SUVEN LIFE SCIENCES LTD (IN) | 2023-01-18 | — | — | EP | disclosed |
| EP-3697790-B1 | HETEROARYL COMPOUNDS AS MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | SUVEN LIFE SCIENCES LTD (IN) | 2023-01-18 | — | — | EP | disclosed |
| US-11234979-B2 | Heteroaryl compounds as muscarinic M1 receptor positive allosteric modulators | SUVEN LIFE SCIENCES LIMITED (IN) | 2022-02-01 | — | — | US | disclosed |
| US-11234979-B2 | Heteroaryl compounds as muscarinic M1 receptor positive allosteric modulators | SUVEN LIFE SCIENCES LIMITED (IN) | 2022-02-01 | — | — | US | disclosed |
| US-20200237761-A1 | HETEROARYL COMPOUNDS AS MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | SUVEN LIFE SCIENCES LIMITED (IN) | 2020-07-30 | — | — | US | disclosed |
| US-20200237761-A1 | HETEROARYL COMPOUNDS AS MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | SUVEN LIFE SCIENCES LIMITED (IN) | 2020-07-30 | — | — | US | disclosed |
| WO-2019077517-A1 | HETEROARYL COMPOUNDS AS MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | SUVEN LIFE SCIENCES LIMITED (IN) | 2019-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200237761-A1 | HETEROARYL COMPOUNDS AS MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | CHRM1, CHRM2, CHRM3 | CHRM1 1/4885AXL 757/4885MERTK 594/4885 |
| US-11234979-B2 | Heteroaryl compounds as muscarinic M1 receptor positive allosteric modulators | CHRM1, CHRM2, CHRM3 | CHRM1 1/4885AXL 798/4885MERTK 664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.